Commercial Manufacturing
Commercial manufacturing is the long middle of the lifecycle: the phase everything before it exists to reach and everything after it exists to protect. Product is made batch after batch — or, in continuous operations, run after run — under the full weight of GMP: 21 CFR 210/211 and its EU counterpart in PIC/S-aligned form, ICH Q7 for active pharmaceutical ingredients, Annex 1 for sterile products with its contamination-control-strategy demand, WHO and PIC/S codes across much of the world, ISO 22716 for cosmetics, and preventive-controls regimes for food. The unit of account is the batch record: instructions executed as written, values recorded contemporaneously, exceptions raised as deviations — and the disposition decision, by the quality unit or, in the EU, through Qualified Person certification under Annex 16, is the moment the whole system's credibility is spent.
What this page does not claim
Phases are an organising device, not a regulatory mandate — real programmes overlap them, and a medical device, a food product and a small-molecule drug traverse them differently. Each page says where the differences bite.
What happens in this phase
Commercial manufacturing is the long middle of the lifecycle: the phase everything before it exists to reach and everything after it exists to protect. Product is made batch after batch — or, in continuous operations, run after run — under the full weight of GMP: 21 CFR 210/211 and its EU counterpart in PIC/S-aligned form, ICH Q7 for active pharmaceutical ingredients, Annex 1 for sterile products with its contamination-control-strategy demand, WHO and PIC/S codes across much of the world, ISO 22716 for cosmetics, and preventive-controls regimes for food. The unit of account is the batch record: instructions executed as written, values recorded contemporaneously, exceptions raised as deviations — and the disposition decision, by the quality unit or, in the EU, through Qualified Person certification under Annex 16, is the moment the whole system's credibility is spent.
The steady state is not static. Continued process verification — Stage 3 of the validation lifecycle — trends process performance and product quality to confirm the validated state persists; the product quality review looks back annually across batches, deviations, complaints, and changes to ask whether the process, its controls, and its specifications remain appropriate. Deviations are investigated to root cause and fed into CAPA; changes to anything the registered details or validated state touch flow through change control with regulatory impact assessed. Materials move under supplier qualification and quarantine discipline; the ERP's batch status gates what can physically be dispensed and shipped; the execution layer enforces the master record on the floor.
Multi-industry differences are real but rhyme. An API plant under ICH Q7 manages impurity carryover and reprocessing rules; a sterile facility lives inside its contamination control strategy, with environmental monitoring as a continuous verdict on it; a device manufacturer runs production and process controls under its quality system with acceptance activities in place of batch certification; a food plant monitors critical control points and verifies its food-safety plan. Quality's posture is the same everywhere: operate the systems that catch problems early — trending, deviation discipline, honest investigation — because in this phase, the alternative to finding your own problems is having a customer, a regulator, or a patient find them.
- Marketing authorisation or equivalent market access in force, with manufacturing matching the registered details.
- The validated state established — process, cleaning, systems, methods — with the continued-process-verification plan active from the first commercial batch.
- Approved master production records, trained personnel, and qualified suppliers for all materials.
- A release mechanism in place: quality-unit disposition or QP certification, with its documented basis.
- Every batch dispositioned on complete records — released, rejected, or otherwise dispositioned with a documented rationale.
- The validated state maintained under trending and periodic review, with drift detected and corrected before it becomes failure.
- Product quality reviews completed on schedule, with actions arising actually implemented.
- Deviations, complaints, and changes managed to closure through the quality system, with recurrence visible and addressed.
SPEQ synthesis. Phase boundaries and gate criteria are an organising device for planning and review, not a regulatory mandate. Real programmes overlap phases and re-enter them; treat these as the questions worth answering, not a compliance checklist.
- Own batch disposition — the release decision and its evidentiary basis, independent of production pressure.
- Run deviation and investigation discipline: root cause pursued past "human error", CAPA effectiveness verified rather than asserted.
- Operate change control across process, facility, materials, and systems, with regulatory impact assessed against the registered details.
- Drive continued process verification and the product quality review as instruments that change decisions, not annual paperwork.
- Maintain supplier qualification and material controls, including the response when a supplier's state of control degrades.
- Executed batch records and the disposition decision for every batch
- Continued-process-verification trends and periodic review outputs
- Product quality reviews / annual product reviews with dispositioned actions
- Deviation investigations, CAPA records, and effectiveness checks
- Change-control records with regulatory impact assessments
- Environmental and utility monitoring records for the operations that require them
- Deviation systems that process paperwork rather than problems — recurring events closed individually, the pattern never confronted.
- Release pressure eroding investigation depth at exactly the moments investigation matters most.
- CPV data collected and filed but not looked at, so a two-year drift arrives as a surprise failure with two years of warnings on record.
- Change control circumvented by "like-for-like" replacements that quietly are not, undoing validation one small decision at a time.
- Supplier qualification as a one-time certificate rather than ongoing verification, discovered when a material change surfaces as a product defect.
Derived from the 8 standards SPEQ maps to this phase, across 5 regulatory bodies: FDA, EMA, ICH, PIC/S, ISO.
FREQUENTLY ASKED
What does batch release actually involve?
A documented judgement that the batch was made and tested in accordance with its requirements — not a signature ritual. The reviewer confirms the batch record is complete and any exceptions investigated and resolved; that in-process and laboratory results meet specification; that the batch was made under the registered process on qualified equipment by trained people; and that nothing open — a deviation, a pending investigation, an environmental excursion — undermines the batch. In the US this is the quality unit's disposition under 21 CFR 211; in the EU, a Qualified Person certifies each batch under Annex 16 and carries personal accountability for it.
What is continued process verification and who does it?
Stage 3 of the process-validation lifecycle: the ongoing programme that confirms, batch over batch, that the process remains in its validated state. Practically it is statistical trending of critical process parameters and quality attributes, with alert behaviour investigated before it becomes rejection; review of deviations, complaints, and yields as corroborating signals; and a defined cadence of assessment. It is jointly owned — manufacturing science or technical services typically run the analytics, quality owns the response — and its output feeds the product quality review. Its failure mode is well known: data faithfully collected, never examined.
How different is commercial manufacture for devices versus medicines?
The skeleton is shared — controlled processes, trained people, records that prove conformity, nonconformance and CAPA discipline — but the release logic differs. A medicine is released batch by batch, each with a disposition decision resting on its record and results. A device flows through production and process controls with acceptance activities at defined points, and conformity attaches to the device and its design rather than to a certified batch; process validation carries extra weight wherever an output cannot be fully verified by inspection. Food sits differently again: monitoring at critical control points, verification of the plan, and lot-level traceability for recall.